scholarly journals Identification of Galectin-3 As a High-Affinity Binding Protein for Advanced Glycation End Products (AGE): A New Member of the AGE-Receptor Complex

1995 ◽  
Vol 1 (6) ◽  
pp. 634-646 ◽  
Author(s):  
Helen Vlassara ◽  
Yong Ming Li ◽  
Farhad Imani ◽  
Donald Wojciechowicz ◽  
Zhi Yang ◽  
...  
Keyword(s):  
Advanced Glycation End Products ◽  
Binding Protein ◽  
Affinity Binding ◽  
Receptor Complex ◽  
Advanced Glycation ◽  
High Affinity Binding ◽  
High Affinity ◽  
Glycation End Products ◽  
End Products ◽  
Galectin 3

Identification of C1q as a Binding Protein for Advanced Glycation End Products

Biochemistry ◽  
2016 ◽  
Vol 55 (3) ◽  
pp. 435-446 ◽  
Author(s):  
Miho Chikazawa ◽  
Takahiro Shibata ◽  
Yukinori Hatasa ◽  
Sayumi Hirose ◽  
Natsuki Otaki ◽  
...  
Keyword(s):  
Advanced Glycation End Products ◽  
Binding Protein ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

scholarly journals Impaired Retinal Angiogenesis in Diabetes: Role of Advanced Glycation End Products and Galectin-3

Diabetes ◽  
2005 ◽  
Vol 54 (3) ◽  
pp. 785-794 ◽  
Author(s):  
A. W. Stitt ◽  
C. McGoldrick ◽  
A. Rice-McCaldin ◽  
D. R. McCance ◽  
J. V. Glenn ◽  
...  
Keyword(s):  
Advanced Glycation End Products ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products ◽  
Galectin 3 ◽  
Retinal Angiogenesis

scholarly journals Co-localization of the Receptor for Advanced Glycation End Products (RAGE) with S100 Calcium-Binding Protein B (S100B) in Human Umbilical Vein Endothelial

2019 ◽  
Vol 63 (1) ◽  
Author(s):  
Iris Serratos ◽  
Ambar López_Macay ◽  
Pilar Castellanos ◽  
José Gilberto Córdoba-Herrera ◽  
Ruy Pérez-Montfort ◽  
...  
Keyword(s):  
Advanced Glycation End Products ◽  
Calcium Binding ◽  
Binding Protein ◽  
Umbilical Vein ◽  
Calcium Binding Protein ◽  
Advanced Glycation ◽  
Human Umbilical Vein ◽  
S100 Calcium Binding Protein ◽  
Glycation End Products ◽  
End Products

The receptor for advanced glycation end products (RAGE) has been involved in the actions of inflammatory proteins such as S100 calcium binding protein B (S100B), among several others. Despite there being many studies available proposing several different modes of interaction between the receptor and the protein, it is necessary to reconcile these binding hypotheses. We evaluated the co-localization of RAGE and S100B in human umbilical vein endothelial cells (HUVEC’s) exposed to acute pro-inflammatory lipopolysaccharide (LPS). Co-localization of the receptor and the protein in umbilical cells exposed to pro-inflammatory stimuli was analyzed using an immunofluorescent assay. RAGE was present in umbilical cells, and its co-localization with S100B was stimulated in the presence of LPS. Our findings suggest an interaction between these proteins, possibly producing early inflammatory responses in umbilical cells. The understanding of the molecular mechanisms of this recognition is relevant to characterize the nature of the signaling associated with this receptor in inflammatory processes.

scholarly journals Pharmacology of polyprenols as adaptogens reducing glycation processes

2013 ◽  
Vol 11 (4) ◽  
pp. 44-53 ◽  
Author(s):  
Natalya Sergeyevna Bakunina ◽  
Ruslan Ivanovich Glushakov ◽  
Natalya Igorevna Tapilskaya ◽  
Petr Dmitriyevich Shabanov
Keyword(s):  
Advanced Glycation End Products ◽  
Clinical Medicine ◽  
Vascular Complications ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products ◽  
Galectin 3 ◽  
Pathological Development ◽  
Specific Receptors ◽  
Significant Attention

Nowadays a significant attention is currently given to the process of glycation which plays an important role in the pathogenesis of vascular complications of diabetes and different neurodegenerative diseases. As a result of inconvertible transformation of early glycation products, stable compounds with different structure are produced - advanced glycation end-products (AGE), which have special patterns leading to pathological development. There are specific receptors of AGE which include phagocyte receptor, RAGE-receptor for advanced glycation end products, and galectin-3. It is necessary to find methods for prevention of development negative processes induced by glycation. It can be administration of glycation inhibitors or the use of compounds, leading to reduction of the level of glycation products, as well as intensification of metabolic processes, which also promotes reduction of glycation. It can also be inhibition of interlocking with receptor and/or post-receptor signaling pathways, which can theoretically reduce the risk of negative phenomena, induced by glycation products. Polyprenols are biologically highly functional active compounds taking part in the process of polysaccharides, glycoproteins, peptidoglycanes and carbohydrate-containing biopolymers biosynthesis. Polyprenols are perspective drugs that can be applied in various fields of experimental and clinical medicine.

Serum levels of advanced glycation end products and their receptors sRAGE and Galectin-3 in chronic pancreatitis

Pancreatology ◽  
2020 ◽  
Vol 20 (2) ◽  
pp. 187-192
Author(s):  
Richard Böhme ◽  
Carla Becker ◽  
Bettina Keil ◽  
Marko Damm ◽  
Sebastian Rasch ◽  
...  
Keyword(s):  
Chronic Pancreatitis ◽  
Advanced Glycation End Products ◽  
Serum Levels ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products ◽  
Galectin 3

scholarly journals Advanced glycation end products, galectin-3, matrix metalloproteinase-9 activity in men with heart failure and concomitant benign prostatic hyperplasia with androgen deficiency

2021 ◽  
Vol 26 (4) ◽  
pp. 67-73
Author(s):  
V.S. Nedzvetsky ◽  
O.Yu. Sirenko ◽  
V.A. Tkachenko ◽  
O.V. Kuryata
Keyword(s):  
Heart Failure ◽  
Benign Prostatic Hyperplasia ◽  
Ejection Fraction ◽  
Advanced Glycation End Products ◽  
Prostatic Hyperplasia ◽  
Testosterone Deficiency ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products ◽  
Galectin 3

The aim was to evaluate serum levels of matrix metalloproteinases-9 activity, advanced glycation end products, galectin-3, C-reactive protein in men with heart failure and benign prostatic hyperplasiawith testosterone deficiency. The testosterone level was determined by immune-enzyme analysis. The content of advanced glycation end products in plasma were analysed by quantitative autofluorescence. The metalloproteinases-9 activity was estimated with fluorometry. The level of galectin-3, C-reactive protein was determined by immune-enzyme analysis. 1st group was made up by the men with heart failure and benign prostatic hyperplasia with testosterone deficiency; 2nd group – by the men without testosterone deficiency. The men with heart failure and benign prostatic hyperplasia with testosterone deficiency had a significantly higher level of advanced glycation end products, galectin-3, matrix metalloproteinases-9 activity in comparison with men with heart failure without testosterone deficiency (p<0.001). Correlation relations between serum advanced glycation end products in patients of the main group with age, ejection fraction, testosterone level were determined – r=0.48 (p<0.001), r=-0.62 (p<0.001), r= -0.66 (p<0.001) respectively. Receiver operating characteristic analysis for predictive role in heart failure with preserved ejection fraction have shown high degree of sensitivity and specificity for advanced glycation end products in serum (p<0.001). Middle-aged men with heart failure with preserved ejection fraction and benign prostatic hyperplasia with testosterone deficiency are characterised by increased serum advanced glycation end products, galectin-3, matrix metalloproteinases-9 activity, C-reactive protein. Serum advanced glycation end products are potential biomarkers of development of heart failure with phenotype of preserved ejection fraction in this cohort.

Sign in / Sign up

Export Citation Format

Share Document